Evidence map›Paper›PMID 40421109›Full record

ArticleResearch (Washington, D.C.)2025

A Domain-Specific Pretrained Model for Detecting Malignant and Premalignant Ocular Surface Tumors: A Multicenter Model Development and Evaluation Study.

Zhongwen Li, Yangyang Wang, Wei Qiang, Xuefang Wu, Yanyan Zhang, Yiyuan Gu, Kuan Chen, Donghua Qi, Liheng Xiu, Yunduan Sun and 9 more

Abstract read
In one paragraph

Article in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zhongwen LiNingbo Key Laboratory of Medical Research on Blinding Eye Diseases, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo 315040, China.ORCID https://orcid.org/0000-0001-9759-7461
Yangyang WangNingbo Key Laboratory of Medical Research on Blinding Eye Diseases, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo 315040, China.
Wei QiangNingbo Key Laboratory of Medical Research on Blinding Eye Diseases, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo 315040, China.
Xuefang WuDepartment of Pathology, The Affiliated People's Hospital of Ningbo University, Ningbo 315100, China.
Yanyan ZhangNingbo Key Laboratory of Medical Research on Blinding Eye Diseases, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo 315040, China.
Yiyuan GuNingbo Key Laboratory of Medical Research on Blinding Eye Diseases, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo 315040, China.
Kuan ChenDepartment of Ophthalmology, Cangnan Hospital, Wenzhou Medical University, Wenzhou 325000, China.
Donghua QiDaqing Eye Hospital, Daqing 163711, China.
Liheng XiuDepartment of Ophthalmology, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Yunduan SunDepartment of Ophthalmology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Daoyuan LiDepartment of Ophthalmology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China.
Yahui XiAnkang Central Hospital, Xi'an Medical University, Xi'an 725000, China.
Shiqi YinNingbo Key Laboratory of Medical Research on Blinding Eye Diseases, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo 315040, China.
Feng WenNingbo Key Laboratory of Medical Research on Blinding Eye Diseases, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo 315040, China.
Mingmin ZhuSchool of Mathematics and Statistics, Xidian University, Xi'an 710071, China.
Yi ShaoDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, National Clinical Research Center for Eye Disease, Shanghai 20080, China.
Jiewei JiangSchool of Electronic Engineering, Xi'an University of Posts and Telecommunications, Xi'an 710121, China.
Wei ChenNational Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
Guohai WuNingbo Key Laboratory of Medical Research on Blinding Eye Diseases, Ningbo Eye Institute, Ningbo Eye Hospital, Wenzhou Medical University, Ningbo 315040, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant and premalignant ocular surface tumors (OSTs) can be sight-threatening or even life-threatening if not diagnosed and treated promptly. Artificial intelligence holds great promise for the early detection of these diseases. However, training traditional convolutional neural networks (CNNs) for this task presents challenges due to the lack of large, well-annotated datasets containing OST images labeled according to histopathological results. Here, we introduce the ocular surface pretrained model (OSPM), a domain-specific pretrained model designed to address the scarcity of labeled data. OSPM is constructed utilizing self-supervised learning on approximately 0.76 million unlabeled ocular surface images from 10 clinical centers across China and can be readily adapted to the OST classification task. We then develop and evaluate an OSPM-enhanced classification model (OECM) using 1,455 OST images labeled with histopathological diagnoses to differentiate between malignant, premalignant, and benign OSTs. OECM achieves excellent performance with AUROCs ranging from 0.891 to 0.993 on internal, external, and prospective test datasets, significantly outperforming the traditional CNN models. OECM demonstrated performance comparable to that of senior ophthalmologists and increased the diagnostic accuracy of junior ophthalmologists. Greater label efficiency was observed in OECM compared to CNN models. Our proposed model has high potential to enhance the early detection and treatment of malignant and premalignant OSTs, thereby reducing cancer-related mortality and optimizing functional outcomes.

Identifiers

PMID40421109
PMCPMC12104561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.